37142-46-4

Basic information

• Product Name: 1-(3-BROMOPROPOXY)-3-CHLOROBENZENE
• Synonyms: 1-(3-BROMOPROPOXY)-3-CHLOROBENZENE;3-Chlorophenoxypropylbromide;1-(3-Bromopropoxy)-3-chlorobenzene,96%;1-(3-Bromopropoxy)
• CAS NO: 37142-46-4
• Molecular Formula: C₉H₁₀BrClO
• Molecular Weight: 249.53
• Mol File: 37142-46-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 139-148 °C (8 mmHg)
• Flash Point: 137.4°C
• Appearance: Clear colorless/Liquid
• Density: 1.454g/cm³
• Vapor Pressure: 0.00166mmHg at 25°C
• Refractive Index: 1.557-1.559
• CAS DataBase Reference: 1-(3-BROMOPROPOXY)-3-CHLOROBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-BROMOPROPOXY)-3-CHLOROBENZENE(37142-46-4)
• EPA Substance Registry System: 1-(3-BROMOPROPOXY)-3-CHLOROBENZENE(37142-46-4)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 36/37/38-20/22
• Safety Statements: 37/39-26-23
• HazardClass: IRRITANT
• Hazardous Substances Data: 37142-46-4(Hazardous Substances Data)

Usage

Chemical Properties

clear colorless liquid

InChI:InChI=1/C9H10BrClO/c10-5-2-6-12-9-4-1-3-8(11)7-9/h1,3-4,7H,2,5-6H2

Upstream product

• 108-43-0 3-monochlorophenol 
• 109-64-8 1,3-dibromo-propane 

Downstream Products

• 5057-51-2 4-(3-chlorophenoxy)butanoic acid 
• 7170-52-7 5-(3-chloro-phenoxy)-valeric acid 
• 401802-33-3 1-(3-(3-chlorophenoxy)propyl)piperazine 

Relevant articles and documents

Discovery of Carboline Derivatives as Potent Antifungal Agents for the Treatment of Cryptococcal Meningitis

Clinical treatment of cryptococcal meningitis (CM) remains a significant challenge because of the lack of effective and safe drug therapies. Developing novel CM therapeutic agents with novel chemical scaffolds and new modes of action is of great importanc

Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ

The free fatty acid receptor 1 (FFA1) and peroxisome proliferator-activated receptors (PPARs) have attracted interest as potent targets for the treatment of metabolic syndrome such as type 2 diabetes. Based on the hypothesis that the dual agonists of PPARs and FFA1 would act as insulin sensitizers and secretagogues by simultaneous activation of PPARs and FFA1, we developed the design strategy to obtain dual PPARs/FFA1 agonist by hybrid FFA1 agonist 1 with PPARδ agonist 2 in consideration of their structural similarity. As expected, systematic exploration of structure-activity relationship and molecular modeling, results in the discovery of lead compound 15, a pan agonist with relative balanced activities between FFA1, PPARγ and PPARδ. The dose-response relationship studies suggested that the pan agonist 15 suppressed the excursion of blood glucose levels in a dose-dependent manner. During a 5-days treatment in ob/ob mice, the pan agonist 15 (100 mg/kg) revealed sustained hypoglycemic effect, even proximity to the most advanced FFA1 agonist (TAK-875, 40 mg/kg), which might be attributed to its pan PPARs/FFA1 activities to simultaneous regulate the mechanism of insulin secretion and resistance. These positive results suggest that the dual PPARs/FFA1 agonists such as lead compound 15 might be novel therapeutic strategy to modulate the complex pathological mechanisms of type 2 diabetes.

The synthesis and preliminary pharmacological evaluation of a series of substituted 4-phenoxypropyl analogues of the atypical antipsychotic clozapine

Herein we report the synthesis, characterization, and preliminary pharmacological activity of a new series of substituted 4′-phenoxypropyl tricyclic analogues of clozapine as potential antipsychotic agents for the treatment of schizophrenia. The lead comp